ROG.VX - Roche Holding AG

Swiss - Swiss Delayed Price. Currency in CHF
218.10
+0.35 (+0.16%)
At close: 5:31PM CEST
Stock chart is not supported by your current browser
Previous Close217.75
Open218.20
Bid220.00 x 243000
Ask218.50 x 260500
Day's Range216.80 - 218.60
52 Week Range212.45 - 273.00
Volume1,593,229
Avg. Volume1,998,708
Market Cap186.931B
Beta0.90
PE Ratio (TTM)21.73
EPS (TTM)10.04
Earnings DateJan 26, 2016 - Feb 1, 2016
Forward Dividend & Yield8.30 (3.81%)
Ex-Dividend Date2018-03-15
1y Target Est259.00
  • Roche CEO 'Very Confident' on European Sales Growth
    Bloomberg Video13 hours ago

    Roche CEO 'Very Confident' on European Sales Growth

    Apr.26 -- Severin Schwan, chief executive officer at Roche Holding AG, discusses first-quarter results, the impact of new medicines on European sales and the company's M&A strategy. He speaks with Bloomberg's Nejra Cehic on "Bloomberg Markets: European Open."

  • Here’s why Amazon won’t go into pharma: hedge fund billionaire
    Yahoo Finance Video2 days ago

    Here’s why Amazon won’t go into pharma: hedge fund billionaire

    Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.

  • Goldman Sachs is offering a 1.6% APY savings account
    Yahoo Finance Video16 days ago

    Goldman Sachs is offering a 1.6% APY savings account

    Wall Street giant Goldman Sachs is making a big push for your savings accounts by offering an annual percentage yield of 1.6%. Yahoo Finance’s Alexis Christoforous, Julia La Roche, and Melody Hahm discuss how the bank is able to offer such a high percentage yield.

  • Reuters12 hours ago

    Biosimilar worries takes shine off Roche's guidance hike

    Cheaper copies of Roche's (ROG.S) Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance from new medicines. "The key focus for today looks likely to be the big hit from biosimilars versus the decent performance from Ocrevus and Hemlibra, with the former likely to dominate," Deutsche Bank analyst Tim Race said, calling Rituxan's drop in Europe "stunning". Roche Chief Executive Severin Schwan remained upbeat.

  • Reuters12 hours ago

    UPDATE 4-Biosimilar worries takes shine off Roche's guidance hike

    Cheaper copies of Roche's Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance from new medicines. Robust demand for new treatments such as Ocrevus for multiple sclerosis and Hemlibra for haemophilia A helped the world's biggest cancer drugs maker to nudge up its full-year sales and profit forecasts on Thursday. "The key focus for today looks likely to be the big hit from biosimilars versus the decent performance from Ocrevus and Hemlibra, with the former likely to dominate," Deutsche Bank analyst Tim Race said, calling Rituxan's drop in Europe "stunning".

  • Roche CEO 'Very Confident' on European Sales Growth
    Bloomberg13 hours ago

    Roche CEO 'Very Confident' on European Sales Growth

    Severin Schwan, chief executive officer at Roche Holding AG, discusses first-quarter results, the impact of new medicines on European sales and the company's M&A strategy. He speaks with Bloomberg's Nejra ...

  • The Wall Street Journal17 hours ago

    [$$] Roche Raises Outlook After Sales Rise

    AG (ROG.EB) raised its outlook on Thursday after first-quarter sales increased, buoyed by the pharmaceutical company’s multiple-sclerosis drug Ocrevus and its HER2 breast-cancer drugs. Switzerland-based Roche said sales rose to 13.6 billion Swiss francs ($13.8 billion) from CHF12.9 billion, beating expectations. According to a FactSet consensus estimate, Roche was forecast to post sales for CHF13.35 billion.

  • Bloomberg18 hours ago

    Roche Lifts Forecast as Bet Outside Cancer Starts to Pay Off

    Roche Holding AG’s bet on fields outside cancer is starting to pay off as the Swiss drugmaker boosted its forecast even as sales of one of its top drugs collapsed in Europe.

  • Financial Times18 hours ago

    [$$] Roche upgrades growth forecast after new drugs boost sales

    Swiss pharmaceuticals group Roche has revised its 2018 sales growth forecast higher after new drugs helped power a 6 per cent rise in the first quarter compared with a year earlier. The Basel-based group said on Thursday it now expected full year sales growth in the “low single-digit” range in constant exchange rates. Roche’s total sales were SFr 13.6bn in the first three months of the year.

  • Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
    Zacks3 days ago

    Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

    Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

  • Reuters3 days ago

    FDA declines to approve Pfizer biosimilar of Roche's cancer drug

    Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks6 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • Roche Hemophilia Drug Gets Breakthrough Therapy Designation
    Zacks8 days ago

    Roche Hemophilia Drug Gets Breakthrough Therapy Designation

    The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters8 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters8 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters8 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • 4,000,000 Reasons to Back China Biotech
    Bloomberg9 days ago

    4,000,000 Reasons to Back China Biotech

    With cancer rates rising, Jiangsu Hengrui has a shot at becoming the next Roche or Pfizer.

  • Reuters10 days ago

    Roche's Hemlibra gets speedy FDA review for wider use

    Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire. The U.S. Food and Drug Administration granted breakthrough therapy designation to the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said on Tuesday. Hemlibra is already approved for people with inhibitors, though Shire is fighting Roche in court seeking to halt expanded use of the medicine.

  • What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength
    Simply Wall St.14 days ago

    What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Roche Holding AG (SWX:ROG) a safer option. Doing business globally, large caps tend to haveRead More...

  • Incyte's Horrible News Derails a Promising Class of Cancer Drugs
    Motley Fool20 days ago

    Incyte's Horrible News Derails a Promising Class of Cancer Drugs

    The failure of an important trial casts doubt on the future of combination immunotherapy.

  • Morningstar28 days ago

    Healthcare: Values Among Drug, Biotech, and Supply Chain Firms

    Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the first- quarter.

  • Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug
    Investor's Business Daily28 days ago

    Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug

    Roche offered additional details Thursday on the deaths of five patients taking its potential blockbuster drug Hemlibra.

  • Reuterslast month

    Tokyo court rejects Shire claim against Roche haemophilia drug

    A Tokyo court has ruled that Shire's (SHP.L) claim against Swiss drugmaker Roche's (ROG.S) new Hemlibra haemophilia medicine should be dismissed, Roche's Japanese subsidiary Chugai said on Wednesday, helping to clear up legal uncertainty over the prospective blockbuster medicine. Chugai, which is 60 percent Roche-owned and which developed Hemlibra, said it expected no change to its financial prospects due to the ruling. "Tokyo District Court rendered a decision in favour of Chugai's claim," Chugai said on its website.

  • Roche Takes Aim at Bristol-Myers Squibb and Merck & Co.
    Motley Foollast month

    Roche Takes Aim at Bristol-Myers Squibb and Merck & Co.

    The biopharma Goliath could soon be battling for billions of dollars in cancer drug sales.

  • Roche's Tecentriq Combo Study Meets Co-Primary Endpoint
    Zackslast month

    Roche's Tecentriq Combo Study Meets Co-Primary Endpoint

    Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival.